Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
Bayer picks Kumquat for $1.3B KRAS collaboration
Bayer has tapped Kumquat for a juicy opportunity, committing up to $1.3 billion to bag a KRAS G12D inhibitor that is on the cusp of the clinic.
Nick Paul Taylor
Aug 12, 2025 6:29am
Expedition inks $645M Fosun deal to bring China asset to US
Aug 11, 2025 11:06am
Ipsen hands back Sutro's ROR1 ADC at center of $875M deal
Aug 8, 2025 6:15am
Gilead hands back one Arcus cancer candidate from $725M deal
Aug 7, 2025 6:35am
Kaken strengthens late-stage HAE portfolio with $32M Astria deal
Aug 6, 2025 10:21am
Lepu supplies 2 T-cell engagers to NewCo in $857M deal
Aug 1, 2025 11:11am
